NBY Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q3

3.00M

+22.9%

-0.210

-64.65%

Estimates Revision

The market is revising No Change the revenue expectations for NovaBay Pharmaceuticals, Inc. (NBY) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by 630.83%.

Revenue Estimates for FY2025

No Change

0.00%

In Past 3 Month

EPS Estimates for FY2025

No Change

0.00%

In Past 3 Month

Stock Price

Go Up

+630.83%

In Past 3 Month

Valuation Metrics

The current forward P/E ratio for NovaBay Pharmaceuticals Inc (NBY.A) is -6.83, compared to its 5-year average forward P/E of -2.08. For a more detailed relative valuation and DCF analysis to assess NovaBay Pharmaceuticals Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-2.08

Current PE

-6.83

Overvalued PE

-0.34

Undervalued PE

-3.82

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-5.53

Current EV/EBITDA

-285.64

Overvalued EV/EBITDA

19.54

Undervalued EV/EBITDA

-30.60

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

1.60

Current PS

61.64

Overvalued PS

7.04

Undervalued PS

-3.85

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

Net Margin - %

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

NBY News & Events

Events Timeline

No data

News

8.5

2025-12-31Benzinga

Cybin Inc Launches $100 Million Equity Program, Shares Drop 6.6%

5.0

2025-12-24Benzinga

Indaptus Therapeutics Completes Board Restructuring and Raises $6 Million

2.0

2025-12-23NASDAQ.COM

Reviva Pharmaceuticals Shares Plunge 45.9%, Dragging Down Drug Sector

People Also Watch

Frequently Asked Questions

What is NovaBay Pharmaceuticals Inc (NBY) stock price today?

The current price of NBY is 8.77 USD — it has decreased -17.58 % in the last trading day.

What is NovaBay Pharmaceuticals Inc (NBY)'s business?

NovaBay Pharmaceuticals, Inc. is engaged in wound care products. The Company manufactures and sells its proprietary form of hypochlorous acid for the wound care market through its NeutroPhase and PhaseOne branded products. NeutroPhase and PhaseOne are used for cleansing and irrigation as part of surgical procedures, as well as treating wounds, burns, ulcers and other injuries.

What is the price predicton of NBY Stock?

Wall Street analysts forecast NBY stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for NBY is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is NovaBay Pharmaceuticals Inc (NBY)'s revenue for the last quarter?

NovaBay Pharmaceuticals Inc revenue for the last quarter amounts to 521.00K USD, decreased % YoY.

What is NovaBay Pharmaceuticals Inc (NBY)'s earnings per share (EPS) for the last quarter?

NovaBay Pharmaceuticals Inc. EPS for the last quarter amounts to -0.22 USD, decreased -88.54 % YoY.

What changes have occurred in the market's expectations for NovaBay Pharmaceuticals Inc (NBY)'s fundamentals?

How many employees does NovaBay Pharmaceuticals Inc (NBY). have?

NovaBay Pharmaceuticals Inc (NBY) has 14 emplpoyees as of January 08 2026.

What is NovaBay Pharmaceuticals Inc (NBY) market cap?

Today NBY has the market capitalization of 1.34B USD.